Line 10: |
Line 10: |
| | | |
| ==Description== | | ==Description== |
| + | ==Prevalence== |
| + | Racehorses 80-100% |
| + | Show horses 60% |
| + | Ponies 78% |
| + | Endurance 67% |
| ==Signalment== | | ==Signalment== |
| + | Foals and young horses in training |
| ==Pathophysiology== | | ==Pathophysiology== |
| + | NOT associated with ''Helicobacter pylori'' and not typically associated with ''Gasterophilus'' |
| ==Risk Factors== | | ==Risk Factors== |
| + | Housing, stress, boredom, training, diet |
| + | Feeding practices: |
| + | *Grain and pelleted feed asssociated with increased serum gastrin (Smyth et al 1988) |
| + | *Eating behaviour (grazing vs feeds) |
| + | *Feed constituents (alfalfa) |
| + | *Individual variability |
| + | Exercise and training |
| + | *Strenuous exercise stimulates gastrin release which has effects on HCL secretion, gastric emptying, gastric blood flow |
| ==Clinical syndrome== | | ==Clinical syndrome== |
| + | Often asymptomatic, may see: |
| + | *Poor appetite |
| + | *Dullness |
| + | *Change in attitude |
| + | *Reduced performance |
| + | *Reluctance to train |
| + | *Poor condition |
| + | *Weight loss |
| + | *Diarrhoea |
| + | *Low-grade colic |
| + | *Excessive recumbency |
| + | *Bruxism (in foals only) |
| + | |
| ==Diagnosis== | | ==Diagnosis== |
| + | Definitive diagnosis requires gastroscopy (cannot do in foals as need to starve prior to exam) |
| ==Laboratory tests== | | ==Laboratory tests== |
| + | No known laboratory markers, attempts to detect occult blood in faeces unreliable in horse |
| ==Endoscopy== | | ==Endoscopy== |
| + | Minimum endoscope length of two metres and 2.8-3.0 metre instruments are reuired for duodenoscopy |
| + | Foals - lesions mainly in glandular epithelium |
| + | Adults - margo plicatus and squamous epithelium |
| ==Pathology== | | ==Pathology== |
| ==Treatment== | | ==Treatment== |
| + | Proton pump inhibitors: only omeprazole (Gastroguard) is licensed for horses. Given PO once daily (4mg/kg) for 3-4 wks, most effective drug at controlling HCl secretion (decreases basal and stimulated release) |
| + | Histamine H2 receptor antagonists: |
| + | *ranitidine 7mg/kg TID for 3-4wks |
| + | *cimetidine 25mg/kg QID for 3-4wks |
| + | Gastric protectants: sucralfate 10-20mg/kg TID for 2-4wks |
| + | Antacids: magnesium and aluminium hydroxides (NOT recommended as have massive rebound effect) |
| ==Prognosis== | | ==Prognosis== |
| ==Prevention== | | ==Prevention== |
| + | Gastroguard at lower dose (1mg/kg) daily for 3-4wks |
| ==References== | | ==References== |
| <references/> | | <references/> |